| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.077 | 0.6 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |